Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Biochemotherapy for melanoma.

P A Philip1, L E Flaherty

  • 1Division of Hematology and Oncology, Karmanos Cancer Institute, Wayne State University, 3990 John R Street, 501 Hudson Building, Detroit, MI 48201, USA. philipp@karmanos.org

Current Oncology Reports
|December 21, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ALLIANCE A022104/NRG-GI010: The Janus Rectal Cancer Trial: a randomized phase II/III trial testing the efficacy of triplet versus doublet chemotherapy regarding clinical complete response and disease-free survival in patients with locally advanced rectal cancer.

medRxiv : the preprint server for health sciences·2024
Same author

Targeting B cells in pancreatic adenocarcinoma: does RESOLVE resolve the question?

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

MicroRNA profiling of diagnostic needle aspirates from patients with pancreatic cancer.

British journal of cancer·2012
Same author

Expression of microRNAs: potential molecular link between obesity, diabetes and cancer.

Obesity reviews : an official journal of the International Association for the Study of Obesity·2011
Same journal

Revisiting the Immunological Landscape of Locoregional Therapies for Gastrointestinal Cancers: A Shift Toward Interventional Immuno-Oncology.

Current oncology reports·2026
Same journal

Anti-PD-1 Combinations: Triplets and Beyond.

Current oncology reports·2026
Same journal

Sacituzumab Tirumotecan Across Gynecologic Malignancies: One Target, Multiple Diseases.

Current oncology reports·2026
Same journal

Clusterin in Head and Neck Squamous Cell Carcinoma: Diagnostic, Prognostic, and Therapeutic Implications.

Current oncology reports·2026
Same journal

Cardiac Risk Without a Roadmap: Lack of Evidence-Based Guidance for Cardiovascular Toxicity of T-Cell Redirecting Therapies.

Current oncology reports·2026
Same journal

Current Understanding of CHIP's Immunobiological Footprint with A Focus on Gastrointestinal Disorders: A Review of the Literature.

Current oncology reports·2026
See all related articles

Combined chemo-immunotherapy (biochemotherapy) shows high response rates for advanced melanoma but increases toxicity. Further trials are evaluating its benefit compared to chemotherapy alone for long-term disease control.

Area of Science:

  • Oncology
  • Immunotherapy
  • Melanoma Research

Background:

  • Advanced melanoma treatment options include chemotherapy (dacarbazine/DTIC) and biologic therapy (interferon-alpha/interleukin-2).
  • Current therapies rarely achieve long-term disease control in metastatic melanoma.

Purpose of the Study:

  • To evaluate the efficacy and toxicity of combined chemo-immunotherapy (biochemotherapy) for advanced melanoma.
  • To compare sequential versus concurrent biochemotherapy regimens.
  • To determine if biochemotherapy offers benefits over chemotherapy alone.

Main Methods:

  • Review of existing treatment strategies for advanced melanoma.
  • Analysis of objective response rates and long-term responders in biochemotherapy studies.
  • Comparison of toxicity profiles between different biochemotherapy schedules.

Related Experiment Videos

Main Results:

  • Biochemotherapy demonstrates high objective response rates (approx. 50%) in metastatic melanoma.
  • A small but significant proportion of patients achieve long-term complete response with biochemotherapy.
  • Concurrent biochemotherapy may be associated with less severe toxicity than sequential regimens.

Conclusions:

  • Biochemotherapy presents a promising strategy for advanced melanoma, offering higher response rates than traditional chemotherapy.
  • While associated with increased toxicity, biochemotherapy can lead to long-term disease control in some patients.
  • Ongoing randomized trials are crucial to definitively establish the benefit of biochemotherapy over chemotherapy alone.